REBOOT
2025
TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT-CNIC)
In 8,505 patients after myocardial infarction with LVEF >40%, beta-blocker therapy did not reduce death, reinfarction, or HF hospitalisation compared with no beta-blocker.
Result
Efficacy: Death from any cause, reinfarction, or hospitalisation for heart failureHR 1.04 (95% CI 0.89-1.22) · P = 0.63
Below 1 favours beta-blocker therapy, above 1 favours no beta-blocker.
Also reported: Beta-blocker vs no beta-blocker neutral over median ~3.7 years in post-MI patients with LVEF >40%.
- Subtopic
- beta-blocker
- Design
- Multicentre open-label RCT with blinded endpoint adjudication (PROBE)
- Relevance
- Important: one of several pillars.
- Source
- Ibáñez B, et al. N Engl J Med. 2025;393(19):1889-1900.doi 10.1056/NEJMoa2504735
Discussion & critique
Open-label design and inclusion of mildly-reduced-EF (41-49%) patients make the preserved-EF message imprecise. With REDUCE-AMI is driving guidelines away from routine beta-blockade after MI when EF is preserved.